Emerging treatments
New systemic antibiotics
Brilacidin and iclaprim are investigational new drugs for antibiotic-resistant bacteria that may have a role in the treatment of complicated impetigo in the future.[37] Delafloxacin, a fluoroquinolone, and omadacycline, a tetracycline, are approved by the US Food and Drug Administration (FDA) for the treatment of acute bacterial skin infections; these are yet to be widely adopted for the treatment of impetigo.[38] In Europe, delafloxacin is approved by the European Medicines Agency for the treatment of bacterial infections of the skin and underlying tissues (acute bacterial skin and skin structure infections) in adults when other medicines are not suitable.
Topical minocycline
Topical minocycline foam is under investigation as a treatment for children with impetigo; additional safety studies are pending.[39]
Use of this content is subject to our disclaimer